Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Jupiter Study: impact on Rosuvastatin

November 13, 2008

Analysis of:CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com

Jupiter study demonstrated significant reduction of cardiovascular morbidity and mortality in patients with high hs-CRP and acceptable lipid profile. This study demonstrates that rosuvastatin might play a major role in modulating inflammation pathways predisposing to cardiovascular diseases. hs-CRP is a systemic inflammation biomarker and might not be useful in clinical practice to identify patients at high risk of developing cardiovascular diseases. However, this study confirms the importance of identifying patients at high risk of developing cardiovascular diseases regardless the use of Framingham risk score.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS